In Brief: Centocor's ReoPro
Executive Summary
Centocor's ReoPro: EPILOG trial halted due to positive interim results in 1,500 patients, Malvern, Penn.-based Centocor announces Dec. 15. The trial, which examined 30-day and six-month outcomes following percutaneous coronary intervention with ReoPro bolus plus 12-hour infusions given either with standard-dose or low-dose heparin in endpoints of death and myocardial infarction, was reviewed by an independent Safety and Efficacy Monitoring Committee, which recommended the trial be terminated because efficacy reached a p-value of <.0001. ReoPro is marketed for reduction of acute cardiac ischemic complications in patients undergoing angioplasty at high risk for abrupt artery closure...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth